Cite
D'Haens GR, Reinisch W, Lee SD, et al. Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study. Inflamm Bowel Dis. 2021;doi: 10.1093/ibd/izab215.
D'Haens, G. R., Reinisch, W., Lee, S. D., Tarabar, D., Louis, E., Kłopocka, M., Klaus, J., Schreiber, S., Il Park, D., Hébuterne, X., Nagy, P., Cataldi, F., Martin, S. W., Nayak, S., Banerjee, A., Gorelick, K. J., & Sandborn, W. J. (2021). Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study. Inflammatory bowel diseases, . https://doi.org/10.1093/ibd/izab215
D'Haens, Geert R, et al. "Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study." Inflammatory bowel diseases vol. (2021). doi: https://doi.org/10.1093/ibd/izab215
D'Haens GR, Reinisch W, Lee SD, Tarabar D, Louis E, Kłopocka M, Klaus J, Schreiber S, Il Park D, Hébuterne X, Nagy P, Cataldi F, Martin SW, Nayak S, Banerjee A, Gorelick KJ, Sandborn WJ. Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study. Inflamm Bowel Dis. 2021 Aug 24; doi: 10.1093/ibd/izab215. Epub 2021 Aug 24. PMID: 34427633.
Copy
Download .nbib